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Background: Esophageal adenocarcinoma has a very poor prognosis unless detected early. The Cytosponge-
trefoil factor 3 (TFF3) is a non-endoscopic test for Barrett esophagus, a precursor of esophageal adenocarci-
noma. Randomised controlled trial data from the BEST3 trial has shown that an offer of Cytosponge-TFF3 in
the primary care setting in England to individuals on medication for acid reflux increases detection of Barrett
esophagus 10-fold over a year compared with standard care. This is an economic evaluation of Cytosponge-
TFF3 screening versus usual care using data from the BEST3 trial which took place between 20th March 2017
and 21st March 2019.
Methods: A Markov model with a one-year cycle-length and a lifetime time horizon was created, adapting
previous modeling work on Cytosponge screening. The impact of one round of Cytosponge screening was
modelled in patients with a median age of 69 years (based on BEST3 trial population). Cost-effectiveness was
expressed as an incremental cost-effectiveness ratio (ICER). Deterministic and probabilistic sensitivity analy-
ses were conducted on model parameters.
Findings: Per person, one round of Cytosponge-TFF3 screening, including confirmatory endoscopy and treat-
ment, in the intervention arm costed £82 more than usual care and generated an additional 0.015 quality-
adjusted life-years (QALYs) at an ICER of £5,500 per QALY gained. Probabilistic sensitivity analysis gave an
ICER of £5,405 (95% CI -£6,791 to £17,600). The average QALY gain per person is small because the majority
of patients in the model will not develop BE and therefore will have no resulting change in their utility, how-
ever the small proportion of patients who are identified with BE dysplasia or cancer derive large benefit. At a
willingness-to-pay threshold of £20,000 per QALY, the probability that Cytosponge-TFF3 was cost-effective
was over 90%.
Interpretation: Using data from a pragmatic randomised trial, one-off Cytosponge-TFF3 screen is cost-effec-
tive relative to usual care for patients with gastro-esophageal reflux disease, despite relatively low uptake
and an older population in this trial setting than previously modelled. Improving Cytosponge-TFF3 uptake
and targeting younger patients is likely to further improve cost-effectiveness.
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The incidence of esophageal adenocarcinoma (EAC) has increased
six-fold in northwest Europe, North America, Australia, and New Zea-
land since the 1990s [1,2], making esophageal cancer a source ofsignificant public health concern. The overall 5-year survival is less
than 20% across multiple high income countries worldwide [3]. One
of the key factors leading to poor outcomes is the late stage at presen-
tation [4]. Reflux symptoms such as recurrent and severe heartburn
are a major risk factor which increases the risk of developing EAC,
and since reflux is highly prevalent (estimates range between 12% to
40% of adults) [5], it is challenging to devise a feasible large-scale
diagnostic and prevention strategy. However, the presence of a pre-
Research in context
Evidence before this study
Barrett esophagus is a pre-cancerous condition which, if diag-
nosed, can permit early detection and curative treatment of
dysplasia and esophageal adenocarcinoma. Randomised con-
trolled trial data from the BEST3 study has shown that offering
a novel non-endoscopic test, the Cytosponge-trefoil factor 3
(TFF3), in the primary care setting in England can diagnose ten
times more Barrett esophagus than usual care over a year. The
cost-effectiveness of this trial is not known.
Added value of this study
This economic model builds upon modeling used by Benaglia
et al. 2013 that used a hypothetical cohort. Our analysis
amended and adapted that model and applied it to clinical trial
data collected from the BEST3 trial. This analysis suggests that
the Cytosponge-TFF3 test is cost-effective in a real world setting
and could be adopted at a lower threshold for willingness-to
pay per QALY gained than previously estimated. In the trial set-
ting patients were older with a lower uptake rate with conse-
quences for cost-effectiveness estimation, improving uptake
and targeting younger patients would add further benefit.
Implications of all the available evidence
The published evidence suggests that the Cytosponge-TFF3 pro-
cedure is cost-effective and affordable if provided as a triage
test for people with gastro-esophageal reflux disease to
increase detection of Barrett esophagus. Although systematic
Cytosponge-TFF3 testing for individuals on medication for
reflux incurs higher costs per person than usual care, and
involves additional diagnostic endoscopy in a minority, Cyto-
sponge-TFF3 also generates additional quality-adjusted life-
years due to earlier cancer diagnosis and curative treatment.
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vides an opportunity to identify a high-risk population so that inter-
vention can be more targeted. There have been significant advances
in cost-effective, outpatient-based endoscopic therapies which are
now recommended for low- and high-grade dysplasia as well as
intramucosal stage-1 cancer in BE with very low rates of recurrence
[68]. These treatment advances substantially mitigate the risks and
side effects from systemic therapy and esophagectomy required for
more advanced disease [9,10].
The major challenge remains identifying individuals with BE,
since using current clinical guidelines, it is estimated that only 20% of
BE is diagnosed and hence the majority of EAC cases are diagnosed de
novo without the opportunity to prevent progression [11,12]. Endos-
copy for all individuals with reflux symptoms would be costly and
pose a logistical challenge for the health system. To overcome this
problem and enable diagnostic triage in primary care, there is consid-
erable interest in developing non-endoscopic approaches [13]. Cyto-
sponge-TFF3 is a non-endoscopic cell collection device coupled with
a laboratory test for the specific biomarker Trefoil Factor 3 (TFF3),
which identifies intestinal metaplasia, i.e. the histopathological hall-
mark of pre-malignant BE. Two clinical studies have previously been
carried out, which have demonstrated the safety, acceptability and
performance characteristics of this test [14]. Recently, a large prag-
matic, randomised, controlled trial (BEST3), involving 13,657 patients
with recurrent reflux symptoms who were on acid-suppressant med-
ication prescribed by their General Practitioner in England has been
reported [15]. This trial showed that the Cytosponge-TFF3 test
administered in the primary care setting, followed by a confirmatoryendoscopy if the Cytosponge-TFF3 result was positive (13%), leads to
a substantial increase in BE cases identified. Attendance rates for
research interventions are commonly challenging. However, despite
only 24% (1654 out of 6834) of patients in the intervention arm
attending to receive this test in this research setting, ten times more
patients were diagnosed with BE in the intervention than in the usual
care arm over 12 months follow-up (in intention-to-treat analysis
and rate ratio after adjustment for cluster randomization 10.6; 95% CI
6.018.8; p < 0.001). In those who underwent the Cytosponge-TFF3
procedure, 131 participants (8% of the 1654 patients who swallowed
a Cytosponge-TFF3 and 59% of the 221 patients receiving a confirma-
tory endoscopy following a positive Cytosponge-TFF3 results) had BE
or cancer diagnosed. Esophago-gastric neoplasia diagnoses were a
secondary endpoint of the trial. Although the numbers were small,
the offer of Cytosponge-TFF3 led to an increased detection of early
neoplasia (dysplastic Barrett esophagus or stage I cancer) compared
with the control arm (9 vs. 0).
Health economic evaluation is an essential part of implementation
of new diagnostic tests, by modeling their impact compared with
standard care (see Fig. 1). Previous economic evaluations of Cyto-
sponge screening have been favourable but have relied on estimates
from previous cohort studies without the availability of randomised
trial evidence to populate the model [16,17]. Using the results of the
BEST3 trial, we conducted a cost-utility analysis of offering Cyto-
sponge-TFF3 testing for patients on long-term treatment with acid
suppressants for gastro-esophageal reflux disease (GERD) compared
with the current standard of care.
2. Methods
2.1. Design and overview
We undertook a detailed analysis of the costs and cost-utility of
the BEST3 trial comparing Cytosponge-TFF3 screening (with a confir-
matory endoscopy for positive TFF3 patients) with the current stan-
dard of care, which entails treatment of heartburn-predominant
symptoms and referral for endoscopy as deemed necessary by the
primary care physician. Consistent with the trial design this consid-
ered one round of Cytosponge-TFF3 screening in a pre-defined
cohort, followed up for one year. We used Markov chains to model
disease state progression for BE through to late-stage EAC, which
were adapted from a previously developed decision analytic model
[16] concerning Cytosponge-TFF3 screening. We did not consider
multiple rounds of screening because the incidence of BE in a cohort
that has already been screened by Cytosponge-TFF3 is not yet known.
The cost of screening was calculated based on the starting proportion
of patients and the uptake rate of Cytosponge-TFF3 in the cohort. We
used a lifetime time horizon from the perspective of the UK National
Health Service (NHS), and a discount rate of 3.5% as per the National
Institute for Health and Care Excellence (NICE) guidelines [18]. Cycle
length in the model was one year. Cost-effectiveness was measured
in terms of an incremental cost-effectiveness ratio (ICER)-the incre-
mental cost per quality-adjusted life-year (QALY) gained.
2.2. Study population values used in the economic analysis
In the BEST3 trial, Cytosponge was offered to individuals aged
50 years and over. However, there was a wide range of participation
across all age groups with a median age of 69 years. Therefore, we
used 69 years as the starting age of the cohort modelled in this eco-
nomic evaluation. 6834 patients were enrolled in the intervention
arm (in the intention-to-treat analysis) and offered the Cytosponge-
TFF3 screening by a written invitation; 2679 (39%) expressed interest
in taking part. Of these, 1750 were eligible, consented and attended
for Cytosponge-TFF3, following which 1654 (95% of those who
attended and 24% of all those in the intervention arm) successfully
Fig. 1. Markov model with transitions for treatment and for natural history (no treatment) patients moving between disease states. BE = Barrett esophagus; NDBE = non-dysplastic
Barrett esophagus; LGD = low-grade dysplasia; HGD = high-grade dysplasia; EAC = esophageal adenocarcinoma.
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women. 311 (19%) of the 1654 participants were offered a repeat
Cytosponge-TFF3 test due to an equivocal or low-confidence
result (meaning gastric columnar cells were not present so could
not guarantee that the distal esophagus had been sampled).
Depending on local capacity and patient preference, 202 partici-
pants attended a second appointment, of whom 190 (94%) suc-
cessfully swallowed the Cytosponge-TFF3. There was one serious
adverse event associated with the Cytosponge-TFF3 test (detach-
ment of the sponge from the thread requiring endoscopy to
retrieve it) and sore throat was the commonest side-effect (4%).
The base-case analysis compared the cost-effectiveness ofCytosponge-TFF3 in a cohort of 6834 patients taking these factors
into account.
2.3. Model structure and disease prevalence
The structure of the Markov model used is shown in Fig. 1. At time
t = 0, patients enter either the Treatment or Natural history model
and the costs of screening are applied. The number of patients start-
ing in each state is given in Table 1. All patients in the Treatment
model receive treatment for BE, and successful patients transition to
the “No BE” (No Barrett esophagus) state. Patients identified as true
positives enter the Treatment model, all other patients including any
Table 1
Starting numbers of patients entering model at different stages of disease identified by the BEST3 trial (under
the assumption that n = 6834 for both the intervention and the usual care arms).
State Intervention arm Usual care arm
Treatment model Natural history model Treatment model Natural history model
No BE 0 6230.6 0 6230.6
NDBE 123 443.6 11.6 555
LGD 1 3.6 0 4.6
HGD 3 10.8 0 13.8
Early EAC 4 14.4 4 14.4
Late EAC 0 0 0 0
BE = Barrett esophagus; NDBE = non-dysplastic Barrett esophagus; LGD = low-grade dysplasia; HGD = high-
grade dysplasia; EAC = esophageal adenocarcinoma.
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False positive patients incur the cost of screening but no BE treatment
costs. The prevalence of BE in this cohort was estimated at 9%.
The sensitivity and specificity of Cytosponge was taken from the
BEST2 trial of 79.9% and 92.4% respectively (not shown) [19]. This
trial was designed to derive accuracy data and the sensitivity used is
from a per protocol analysis that includes inadequate samples with-
out a repeat examination to provide a conservative, base case. We
assumed that the confirmatory endoscopy with biopsy that follows a
positive TFF3 test result had an effective sensitivity and specificity of
1 (gold-standard) for the purposes of the model, in line with assump-
tions taken by previous economic models [16,17,20]. This approach
takes into account the face validity of a negative endoscopy test in
that clinicians typically do not re-order endoscopy following negative
findings, even though the sensitivity of endoscopy is less than 100%.
Therefore, we are in effect modeling “endoscopy detectable BE”. Half-
cycle correction was applied. See Appendix for further details on
methods.
Treatment data for PPI drugs and patients with EAC was taken
from trial data. Late-stage cancer was treated with palliative care.
Utilities were assigned regardless of whether any disease had been
identified. Key model outputs are given in Table 2.2.4. Costs and utilities
The costs of testing using the Cytosponge-TFF3 are high estimates
based on introducing Cytosponge on a limited adoption basis since
there is currently no National Schedule for this test. These include
the device and centralised laboratory processing, the TFF3 antibody,
manual pathology reporting costs, the confirmatory endoscopy, and
the time of the nurse administering the test (see Appendix). Treat-
ment costs include proton pump inhibitor and histamine 2 receptor
antagonists drugs, endotherapy, esophagectomy, chemotherapy, and
palliative care costs. Unit costs were taken from published sources
[21,22]. Palliative care costs were applied to anyone who died of lateTable 2
Key model outputs, showing number of patients in the model who received sc
esophageal adenocarcinoma Nb.
Model outputs Intervention arm (base cas
Cytosponge uptake at 24%
Number invited for Cytosponge-TFF3 screening 6834
Number who had Cytosponge-TFF3 test 1654
Number who had endoscopy 198
Number who start with or develop LGD* 344
Number who start with or develop HGD 143
Number who start with or develop early EAC 162
Number who die of EAC 153
* The intervention arm had a slightly higher number of LGD cases because a) m
who were treated for LGD returned to ‘No BE’, and therefore had a chance of get(stage 4) EAC. We calculated mean and standard deviation costs for
both arms for each cost component and all components combined
(Table 3). Utilities and disutilities were derived from the literature
(see Appendix) [20,2325]. Disutilities were applied to stricture (2
weeks), perforation, EMR and RFA surgery (4 weeks), chemotherapy
(4.5 months), and esophagectomy (3 months). The endoscopy costs
were from UK tariffs which are likely to be an underestimate for pri-
vate health care systems, and so higher endoscopy costs were
explored in sensitivity analysis.2.5. Transition probabilities, effectiveness and model structure
Natural history transition probabilities (se Appendix) were drawn
from the literature [6,16,20]. The effectiveness of treatment for RFA
and EMR was taken from published sources [7,26]. The effectiveness
of esophagectomy was estimated by using 90-day mortality data
taken from a National EAC audit [27]. We developed a new economic
model, building on previous research into Cytosponge screening by
Benaglia et al. [16] with adaptations to the model structure as well as
parameters used for the natural history of BE and EAC treatment costs
(Fig. 1,and Appendix).2.6. Sensitivity analysis and budget impact
To explore the uncertainty around model parameters, we under-
took probabilistic sensitivity analysis (PSA) and deterministic sensi-
tivity analysis (DSA). PSA randomly and simultaneously varies all
parameters within independent probability distributions, which we
simulated 1000 times. The PSA results are illustrated using a cost-
effectiveness plane, and a cost-effectiveness acceptability curve. The
resulting ICER was presented with a 95% confidence interval.
DSA varies all parameters individually in order to determine the
effect of each upon the ICER, identifying which parameters have the
largest impact on cost-effectiveness. For the DSA, we varied the mean
+/- 20% for all parameters, with the exception of: cytosponge uptakereening, developed Barrett esophagus, and who developed and died from
e analysis) Intervention arm (alternative scenario) Usual care arm








ore patients were treated for LGD in the intervention arm; and b) patients
ting worse again and progressing to NDBE and then LGD (and so on).
Table 3
Main results (per patient), showing the breakdown of costs and benefits for the
intervention and usual care arms that make up the incremental cost-effectiveness
ratio.
Intervention arm Usual care arm
Mean SD Mean SD Mean Difference
Screening cost £77 £83 £1.14 £1.21 £76
Treatment cost £489 £302 £482 £306 £7
Total cost £565 £313 £48 £306 £82
QALYs gained 9.926 0.444 9.911 0.442 0.015
Life Years gained 13.027 0.545 13.016 0.545 0.011
ICER £5500
Cost values given in GBP.
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ing the model that was varied from 50 to 74 (ranging from the rec-
ommended starting age of screening to the upper quartile from the
BEST3 trial data); prevalence of BE which was varied from 4% to 12%;
Cytosponge cost which we varied from £144 to £344 per test; and
Cytosponge sensitivity which we varied from 76.4% to 83.0% as per
the BEST2 trial results [19].
Using the results of the analysis, we calculated the potential bud-
get impact that adopting the Cytosponge-TFF3 would mean for large-
scale role out within the NHS.
An alternative screening scenario, consistent with BEST3 was con-
sidered in which a second Cytosponge test was administered in a
subset of patients following an inconclusive sample. 10% (202/1952)Fig. 2. Cost-effectiveness plane. Each diamond represents the results of one simulation of the
years (QALYs) gained. The base-case result of an incremental £81 and 0.015 QALYs is highligh
incremental QALYs on the x-axis.of Cytopsonge tests were re-administered in the BEST3 trial, and the
impact of this on costs and QALYs was estimated in this scenario. This
scenario also increases the sensitivity to >90% but we kept our con-
servative estimate of 79.9% [19].
2.7. Role of the funding source
The BEST3 trial was funded by Cancer Research UK, National Insti-
tute for Health Research, the UK National Health Service, Medtronic,
and the Medical Research Council. Named authors had access to the
data and decided to submit the manuscript for publication.
3. Results
3.1. Cost of screening
In the base-case analysis there were 1654 Cytosponge tests
administered and 198 confirmatory endoscopies, giving a total cost
of £524,716, or £77 per GERD patient. In the usual care arm, in which
endoscopy was performed if deemed warranted by the family practi-
tioner according to patient symptoms, there were 16 endoscopies
performed (with biopsy) at a cost of £7808 or £1 per GERD patient.
3.2. Base-case analysis
The cost of one round of Cytosponge-TFF3 screening, including
treatment for BE and EAC identified, and palliative care, was an incre-
mental £82 per GERD patient compared with usual care. The Cyto-
sponge arm generated an additional 0.015 QALYs per patient, andprobabilistic sensitivity analysis in terms of per-person costs and quality-adjusted life-
ted for reference. Graph shows incremental cost per person in GBP(£) on the y-axis and
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gained on average 0.011 additional life years in the Cytosponge arm
vs usual care.
3.3. Probabilistic sensitivity analysis
The PSA was used to estimate the uncertainty around the base-
case estimates for the incremental mean cost per GERD patient and
the incremental mean number of QALYs per GERD patient for both
the Cytosponge and usual care arms. For the Cytosponge arm, these
were an average of £582 (SD £313) and 9.92 QALYs (SD 0.44). For the
usual care arm, these were an average of £504 (SD £306) and 9.91
QALYs (SD 0.44), which means an incremental cost of £78 (SD £86)
and 0.015 QALYs (SD 0.002), giving an ICER of £5405 (95% CI 6791
to £17,600). At a willingness-to-pay threshold of £20,000 per QALY,
the probability that the Cytosponge-TFF3 was cost-effective relative
to usual care was 97% (Figs. 2 and 3). The results of the 1000 PSA sim-
ulations are presented in Fig. 2, plotted on the cost-effectiveness
plane. The likely cost-effectiveness of Cytosponge vs usual care at
increasing thresholds of willingness-to-pay is plotted shown by the
cost-effectiveness acceptability curve in Fig. 3. This suggests that
Cytosponge screening is the more cost-effective option.
3.4. Deterministic sensitivity analysis
The DSA shows that there were a number of parameters that had a
large effect on the ICER, and these are presented and ranked on the
tornado plot in Fig. 4. The parameters that had the largest impact
were: the utility of the ‘No BE’ health state; the average starting ageFig. 3. Cost-effectiveness acceptability curve. The curve illustrates the probability that the in
below the willingness-to-pay threshold of £20 000 per quality-adjusted life-year (QALY) gain
percentage change of being cost-effective on the y-axis and willingness-to-pay per QALY gainof the patients (at time t = 0); the prevalence of BE; the utility of the
‘LGD’ health state; the cost of Cytosponge and the uptake rate of
Cytosponge.
Changing the utility of the health states ‘No BE’ and ‘LGD’ saw the
ICER range from £3756 to £10,268 for ‘No BE’, and from £4488 to
£7102 for ‘LGD’. That these parameters had a large impact is due to
the fact that most patients in the model were in either of these health
states at any given time (other than ‘dead’). Varying the average start-
ing age saw the ICER range from £1952 to £8286. Varying the preva-
lence of BE saw the ICER range from £4352 to £18,256 (with a higher
prevalence meaning Cytosponge is more cost-effective). Varying the
cost of Cytosponge saw the ICER range from £3788 to £7212, with
lower costs producing lower ICERs. Varying the uptake of Cytosponge
saw the ICER range from £5008 to £7742, and at the upper value of
50% uptake the cost-per-patient was £173, along with fewer cases of
HGD, EAC, and EAC mortality shown in Table 2.3.5. Readministered cytosponge scenario
In the scenario where patients with inconclusive Cytosponge tests
were invited for a repeat test, there were 202 additional Cytosponge
tests administered and 23 additional confirmatory endoscopies. This
resulted in identification of an additional 0.1 LGD, 1.0 HGD, 2.0 early
EAC and 3.1 EAC deaths vs the base case analysis. The ICER was
£5305, and the average cost of screening per person was £92.cremental cost-effectiveness ratios produced by the probabilistic sensitivity analysis are
ed recommended by the National Institute for Health and Care Excellence. Graph shows
ed on the x-axis in GBP(£).
Fig. 4. Tornado plot for the deterministic sensitivity analysis. Each parameter in the model is illustrated. The effect on the base case incremental cost-effectiveness ratio (ICER) of
£5500 of reducing (low) or increasing (high) a given parameter can be observed in the ‘low’ and ‘high’ horizontal bars. BE = Barrett esophagus, LGD = low-grade dysplasia,
EAC = esophageal. ICER values given in GBP(£).
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Using an estimated additional cost-per-patient of £82, we calcu-
lated that the total budget impact of conducting one round of Cyto-
sponge-TFF3 screening in the UK would affect approximately
262,941 patients with GERD eligible for Cytosponge screening
(assuming uptake of 24%) and would cost £21,636,235. This cost
would be spread over roughly 29 years at an annual cost of £746,077.
4. Discussion
The introduction of Cytosponge-TFF3 screening is cost-effective
relative to usual care, even at the relatively modest uptake of 24%
and with a significantly older population than has been previously
modelled. The base-case ICER of £5500 proved largely unresponsive
to uncertainty around key parameters such as Cytosponge-TFF3 cost
and endoscopy cost, increasing to a maximum of £18,256 per QALY
gained in the deterministic sensitivity analysis (Fig. 4). This is a lower
ICER than previously reported in Benaglia et al. [16] The favourable
ICER is largely due to the fact that the usual care arm detected very
few cases of BE relative to Cytosponge-TFF3, and since this model is
underpinned with clinical trial data from a more real-world setting,
we have much more confidence in these results.
As shown by the tornado plot, the cost-utility estimated by this
model could be further improved by increasing the uptake of the
Cytosponge-TFF3. The uptake is likely to be dependent on how the
offer is made and inviting patients with symptoms at their general
practitioner consultation or when ordering a repeat prescription is
likely to make people more willing to take the test compared to anunexpected written invitation to take part in a trial. Simply because
there are a comparatively large number of patients with NDBE,
improving their health-related quality of life would also see a large
improvement on the cost-effectiveness of Cytosponge-TFF3 screen-
ing. For example, patients with BE with the lowest risk of progres-
sion, i.e. with less than 2 cm of segment length, younger age, female
sex [28], do arguably not require regular surveillance and clinical
guidelines are likely to reflect this in coming years. Work is ongoing
so that additional risk stratification biomarkers applied to the Cyto-
sponge-TFF3 test will enable monitoring to be performed non-endo-
scopically [19].
It ought to be noted that the absolute gain in QALYs is small
because the majority of patients in the model will not develop BE and
therefore will have no resulting change in their utility (which is based
on each disease state). However, for the small number of patients
who are detected early and treated the QALY gain is substantial, and
indeed the utility gain is greater than the length of life gained
through reduced mortality (demonstrated by the fact that the QALY
gain is larger than the life years gain between the arms).
Strengths of this analysis include the use of data from a real-world
clinical trial, such that it was not reliant upon estimates of prevalence
and incidence which often have a large degree of uncertainty around
them. We used conservative estimates for the Cytosponge-TFF3
device and laboratory costs, which are likely to come down as
manufacturing and processing throughput increases. Using the sensi-
tivity and specificity of a BE screening tool to estimate the false nega-
tives, coupled with real-world data on all true positives, should give a
robust estimate of the true prevalence of BE in GERD patients. Addi-
tionally, our method of estimating prevalence yielded a similar
8 N. Swart et al. / EClinicalMedicine 37 (2021) 100969proportion of cases of BE to that of other published work [16]. We
also point out that we took endoscopy, the gold standard, to be 100%
accurate which we know is not the case with increasing data on post-
endoscopy esophageal adenocarcinoma suggesting a 313% miss
rate [29].
Limitations include the lack of available data on transition proba-
bilities between stages of EAC, and lack of available data needed to
estimate the standard errors of our PSA parameters. We have tried to
overcome this by using values that will bias against the intervention.
Updating this analysis with treatment transition probabilities for
NDBE would be a recommendation for further study. Additionally,
the model predicts 20 fewer EAC deaths in the Cytosponge arm
(although this was not the model’s primary function and we lacked
robust data on EAC progression risk) and again this would be affected
by the uptake of the test (Table 2). Microsimulation models are
required to evaluate this further. Lastly, the median age from BEST3
used here is for those who took the Cytosponge test and is skewed by
more elderly persons accepting a postal invitation offer for research
and having time to attend a trial test. A screening program targeting
slightly younger participants will likely see additional benefit as
younger participants will accrue more QALYs as they stay in better
health states for longer. Similarly, a screening intervention focusing
on male patients is likely to have a positive effect on the ICER, consid-
ering the comparatively higher risk of BE progression in males [28]
and therefore the potential gain in quality and length of life from
early diagnosis and treatment.
This analysis considered only one round of screening for one
cohort. Continued monitoring of the BEST3 cohort will allow this
analysis to be updated when the post-screening incidence of BE can
be identified in the BEST3 cohort, and future economic modeling will
help to inform whether a program of screening every 3, 5 or 10 years,
for example, would be more cost-effective. In addition, as evidence
accrues on predictive risk scores for BE and EAC, this may help to
identify the optimum group for targeted screening strategies to be
cost-effective [30], including considering enriching the population at
risk without reliance on a history of reflux [31].
In conclusion, the BEST3 trial showed that an offer of Cytosponge-
TFF3 screening was very effective at identifying cases of BE and EAC
relative to identification of BE by endoscopy based on referrals. This
economic evaluation has shown that the Cytosponge-TFF3 yielded
modest benefits at a low cost compared to usual care. This is largely
because the majority of patients screened did not have BE, and most
of the cases detected tended to be milder cases (NDBE), which incur
relatively little cost. Except for the upfront screening cost, the total
cost of one round of Cytosponge-TFF3 screening would likely be
spread over many years as most cases of BE found were of low sever-
ity and relatively stable. These data are encouraging for the rapidly
expanding research efforts to develop non-endoscopic screening
strategies for Barrett esophagus [3234] and paves the way for fur-
ther modeling studies to evaluate cost-effectiveness and health bene-
fits in a range of health care systems.
Data sharing
The trial is a cluster randomised trial with aggregated data for the
usual care arm and therefore individual level data will only be avail-
able for the Cytosponge intervention patients. GP-level data and indi-
vidual data will be available via the University of Cambridge’s data
repository (https://www.data.cam.ac.uk/repository). The BEST3 web-
site (https://www.best3trial.org/) is available for more information
and contact details.
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